These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 16782768

  • 1. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [Abstract] [Full Text] [Related]

  • 2. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A.
    Clin Chem Lab Med; 2005 Sep; 43(3):275-9. PubMed ID: 15843230
    [Abstract] [Full Text] [Related]

  • 3. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
    Eiermann B, Edlund PO, Tjernberg A, Dalén P, Dahl ML, Bertilsson L.
    Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
    [Abstract] [Full Text] [Related]

  • 4. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
    Dalén P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR.
    Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
    [Abstract] [Full Text] [Related]

  • 5. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
    Cerqueira PM, Mateus FH, Cesarino EJ, Bonato PS, Lanchote VL.
    J Chromatogr B Biomed Sci Appl; 2000 Dec 01; 749(2):153-61. PubMed ID: 11145052
    [Abstract] [Full Text] [Related]

  • 6. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
    Pereira VA, Auler JO, Carmona MJ, Mateus FH, Lanchote VL, Breimer DD, Santos SR.
    Braz J Med Biol Res; 2000 May 01; 33(5):509-14. PubMed ID: 10775881
    [Abstract] [Full Text] [Related]

  • 7. Determination of debrisoquine and metabolites in human urine by gas chromatography-mass spectrometry.
    Daumas L, Sabot JF, Vermeulen E, Clapot P, Allegre F, Pinatel H, Boucherat M, Francois B.
    J Chromatogr; 1991 Sep 18; 570(1):89-97. PubMed ID: 1797839
    [Abstract] [Full Text] [Related]

  • 8. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
    Cooke BR, Bligh SW, Cybulski ZR, Ioannides C, Hall M.
    Drug Metab Dispos; 2012 Jan 18; 40(1):70-5. PubMed ID: 21976620
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
    Wink J, Veering BT, Kruit M, Burm AG, Huledal GA, Ekström GY, Stienstra R, van Kleef JW.
    Anesth Analg; 2008 Jan 18; 106(1):143-6, table of contents. PubMed ID: 18165569
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P, Dahl M, Andersson K, Bertilsson L.
    Br J Clin Pharmacol; 2000 Feb 18; 49(2):180-4. PubMed ID: 10671914
    [Abstract] [Full Text] [Related]

  • 12. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ, Mueller HK, Dick B, Meyer UA.
    Gastroenterology; 1983 Sep 18; 85(3):682-92. PubMed ID: 6603386
    [Abstract] [Full Text] [Related]

  • 13. Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers.
    Kortunay S, Bozkurt A, Basci NE, Kayaalp SO.
    Eur J Drug Metab Pharmacokinet; 2002 Sep 18; 27(3):171-4. PubMed ID: 12365197
    [Abstract] [Full Text] [Related]

  • 14. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
    Lightfoot T, Ellis SW, Mahling J, Ackland MJ, Blaney FE, Bijloo GJ, De Groot MJ, Vermeulen NP, Blackburn GM, Lennard MS, Tucker GT.
    Xenobiotica; 2000 Mar 18; 30(3):219-33. PubMed ID: 10752638
    [Abstract] [Full Text] [Related]

  • 15. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
    Dalén P, Dahl ML, Roh HK, Tybring G, Eichelbaum M, Wilkinson GR, Bertilsson L.
    Br J Clin Pharmacol; 2003 Jun 18; 55(6):630-4. PubMed ID: 12814461
    [Abstract] [Full Text] [Related]

  • 16. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr 18; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 17. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J, Lindberg R, Huupponen R, Iisalo E.
    Br J Clin Pharmacol; 1988 Dec 18; 26(6):791-5. PubMed ID: 3242585
    [Abstract] [Full Text] [Related]

  • 18. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
    Simooya OO, Sijumbil G, Lennard MS, Tucker GT.
    Br J Clin Pharmacol; 1998 Mar 18; 45(3):315-7. PubMed ID: 10896408
    [Abstract] [Full Text] [Related]

  • 19. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
    LLerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P.
    Ther Drug Monit; 2001 Dec 18; 23(6):616-20. PubMed ID: 11802093
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A, Dorado P, Peñas-Lledó EM.
    Pharmacogenomics; 2009 Jan 18; 10(1):17-28. PubMed ID: 19102711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.